Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In heart failure, chronic therapy with beta-receptor blocking agents improves cardiac performance and prolongs survival, but the exact mechanisms whereby these compounds exert such beneficial effects remain unclear. One hypothesis is that beta-blockers improve the energetic balance of the heart and act, at least in part, by preserving high-energy phosphate metabolism. In experimental heart failure caused by chronic coronary ligation in the rat, the beta-blocker bisoprolol significantly improves cardiac function in parallel to preservation of phosphocreatine stores and intracellular ATP transfer rates, suggesting improved cardiac energetics as one mechanism of action. Clinical evidence on energetic effects of beta-blockers is still only anecdotal. We showed in four patients with dilated cardiomyopathy that the phosphocreatine/ATP ratio, measured by 31 p-MR spectroscopy, increases during chronic metoprolol therapy. Currently, a larger systematic placebo-controlled clinical trial of the functional and energetic effects of bisoprolol in dilated cardiomyopathy, followed sequentially by MR imaging and spectroscopy, is underway, which, when completed, should reveal whether beta-blockers in fact preserve high-energy phosphate metabolism in human heart failure.

Type

Journal article

Journal

Journal of Clinical and Basic Cardiology

Publication Date

13/10/2000

Volume

3

Pages

119 - 122